• In August 2026, Insulet Corporation reported second-quarter 2026 results showing revenue of US$801.7 million and net income of US$95.0 million, with diluted earnings per share from continuing operations of US$1.37, all higher than the same period a year earlier.
• For the first half of 2026, Insulet’s revenue of US$1.56 billions and net income of US$186.1 million highlight stronger profitability alongside its new guidance calling for double‑digit GAAP revenue growth for the third quarter and full year.
• With management now projecting double‑digit GAAP revenue growth for 2026, we’ll consider how this updated outlook shapes Insulet’s investment narrative.

We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Insulet Investment Narrative Recap

To own Insulet, you need to believe in long term adoption of its Omnipod platform across both type 1 and type 2 diabetes, supported by recurring pod revenue. The latest results and double digit revenue guidance reinforce that growth remains a key near term catalyst, while the ongoing Class I pod recalls keep product quality and regulatory scrutiny as the most important current risk. So far, the earnings strength appears to offset the immediate financial impact of these issues.

The most relevant recent announcement here is management’s updated outlook calling for 17% to 19% GAAP revenue growth for the third quarter and 21% to 23% for 2026. That guidance, coming just weeks after large scale recalls and corrections across Omnipod pods, will likely shape how investors weigh the growth opportunity in newer launches like Omnipod 5 and expansion into markets such as Spain against the operational and quality risks exposed this year.

But behind the strong revenue guidance, the scale and severity of recent Class I recalls is something investors should be aware of and...

Insulet's narrative projects $4.8 billion revenue and $734.9 million earnings by 2029.

Uncover how Insulet's forecasts yield a $235.54 fair value, a 64% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming about US$5.2 billion in 2029 revenue and US$804.6 million in earnings, which contrasts sharply with concerns about manufacturing scale and recall risk, and shows how differently you and other investors might reassess those views after this quarter’s results and guidance.

Explore 7 other fair value estimates on Insulet - why the stock might be a potential multi-bagger!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Insulet research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Insulet research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Insulet's overall financial health at a glance.

No Opportunity In Insulet?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• AI is about to change healthcare. These 44 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 50 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.